Self-administered HPV Test Market

Self-Administered HPV Test Market Outlook (2024 to 2034)

The global self-administered HPV test market is evaluated to reach a valuation of US$ 472.1 million in 2024 and further expand at a CAGR of 18.1% to end up at US$ 2.48 billion by the year 2034.

As a member of the papillomaviridae family, the human papillomavirus (HPV) is the most prevalent sexually transmissible infection worldwide. The double-stranded DNA tumor virus known as the human papillomavirus multiplies epithelial cells on the cutaneous and mucosal surfaces. HPV is divided into two classes, such as low-risk HPVs and high-risk HPVs, based on the level of danger involved.

The HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 are among the approximately 14 high-risk HPV types. Cervical and vaginal cancer are now well recognized to be caused by high-risk strains of HPV. With about half of all cervical cancers being of the HPV 16 type, which is the most carcinogenic, combined HPV 16 and 18 types account for around 70% of cervical malignancies.

Fact.MR, in its newly self-administered HPV test industry analysis states, that in the world, cervical cancer ranks among key cancer types that affect women. An estimated 604,000 new cases and 342,000 associated fatalities occurred in 2020. If cervical cancer is identified early on, treated appropriately, and immunizations are successful, the disease is easily and most effectively cured.

92% is a fairly high 5-year survival rate if the condition is discovered early. With the right care and therapy, malignancies are treated in their later stages. The WHO approved a global strategy in 2020 with the goal of eliminating cervical cancer, and by 2030, 70% of women worldwide should have had routine testing.

Report Attribute	Detail
Self-administered HPV test Market Size (2024E)	US$ 472.1 Million
Forecasted Market Value (2034F)	US$ 2.48 Billion
Global Market Growth Rate (2024 to 2034)	18.1% CAGR
North America Market Value (2024E)	US$ 168.6 Million
Mexico Market Value (2034F)	US$ 94.51 Million
Cervical Cancer Segment Growth Rate (2024 to 2034)	18.1% CAGR
South Korea Market Value (2034F)	US$ 89.7 Million
Key Companies Profiled	Roche; Becton, Dickinson and Company; Hologic; Abbott Laboratories; Qiagen NV; Biocare Medical LLC; F.Hoffmann-La Roche Ltd; Mylab Discovery Solutions Pvt. Ltd; Thermo Fisher Scientific

Human papillomaviruses (HPV) are the group of viruses of around 200 types. There are two categories of HPV, as mentioned in the self-administered HPV test industry outlook. Low-risk HPV causes warts, which are non-cancerous tumours and the high-risk HPV causes various cancers, such as cervical cancer, vaginal cancer, vulvar cancer, oral cancer, anal and penile cancer.

According to WHO, 90% of the death occurred from cervical cancer in 2015 in low and mid-income countries, which are complied in the self-administered HPV test industry analysis by Fact.MR analysts. In the report by CDC (Centers for Disease Control and Prevention), every year almost 12,000 women get affected with cervical cancer in the US and around 4000 dies from it.

The cytological test called Pap smear test along with the HPV DNA test (HPV test) are used in cervical cancer screening. It is preventable cancer with regular screening tests and early treatment.

Pap test is used to detect cell changes or abnormal cells in cervix whereas HPV test used to find the presence of HPV virus in the cervix. Nowadays self-administered HPV test is available. The use of self-sampling HPV DNA test as the primary screening test is more suitable as compared to the conventional Pap test that requires sampling to be performed by the health professionals.

The self-sample test opens the chances to remove some of the barriers that discourage women to participate in the screening test. In self-administered test kit is provided to the women and the sample collection is done by them followed by an examination in the laboratory.

Growing prevalence of the sexually transmitted diseases and increase in the cervical cancer cases in women aged above 30 years are the driving factors of the g market. Novel kits have been designed, which allow women to self-screen the samples, as per the self-administered HPV test industry outlook.

This self-administered test is easy to perform and it is relatively cheap compared to the conventional test. These factors are expected to boost up the self-administered HPV test market. Moreover, Self-sampling is less invasive, requires less time to perform as well as it allows for privacy and reduces pain and discomfort among women rising up the self-administered HPV test market.

Self-administered HPV test is used in fewer resource areas where women are underscreened or never screened and where chances of cervical cancer are very high increases the demand of self-administered HPV test kits in such regions.

The self-administered HPV test is less specific as compared to the conventional cytological test adds to the limitation of self-administered HPV test market. Less adoption of such self-administered kits by the healthcare professional as well as by the women, limit the overall growth of the market.

Additionally, the individual performing the self-administered test should be knowledgeable and should perform and collect the sample with high efficacy. These factors add up the limitation of self-administered HPV test market in low healthcare facilities areas. Cultural sensitivity issues in rural areas also limit the self-administered HPV test market.

The report covers exhaustive analysis on:

• Market Segments
• Market Dynamics
• Market Size Analysis
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Value Chain Analysis

The regional analysis includes:

• North America (United States, Canada)
• Latin America (Mexico. Brazil)
• Western Europe (Germany, Italy, France, United Kingdom, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
• Eastern Europe (Poland, Russia)
• Asia-Pacific Excluding China and Japan (India, ASEAN, Australia & New Zealand)
• China
• Japan
• The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance

Segmentation of the Self-administrated HPV Test Market Research

• By Technology :

  • DNA-based Assays
  • RNA-based Assays

• By Disease Indications :

  • Cervical Cancer
  • Vaginal Cancer

• By End Users:

  • Clinics
  • Home-based settings
  • Healthcare Centers
  • Diagnostic Centers

• By Region :

  • Northeast
  • Southeast
  • West
  • Southwest
  • Midwest